Can TopGum turn brain and eye health into the next major gummy growth category?
TopGum is targeting cognition and eye health with new gummies, but evidence, claim discipline and brand adoption will decide commercial impact.
Pharma & Biotech
Pharma & Biotech
Mentari just raised another $200m for migraine, but can its PACAP antibodies clear the clinical test?
Mentari adds $200 million to fund MT-001 and MT-002 through Phase 2a, extending its PACAP migraine runway into 2029 ahead of the InMed merger.
Pharma & Biotech
Curis expands emavusertib PCNSL response pool as TakeAim CLL enrolment accelerates
Curis reports updated emavusertib responses in PCNSL and faster CLL enrolment, while durability, safety and funding remain critical tests.
Pharma & Biotech
Why Royalty Pharma is betting up to $425m on Neurimmune’s Phase 3 heart drug
Neurimmune sells part of its cliramitug royalty to Royalty Pharma for up to $425 million as the ATTR-CM antibody advances through Phase 3.
Pharma & Biotech
Can BostonGene’s AI reveal which gastrointestinal cancer patients will benefit from ICI-PDT therapy?
BostonGene and Kyoto University will use multiomic AI to seek response biomarkers in a Phase II ICI-PDT trial for advanced GI cancers.
Pharma & Biotech
Summit Therapeutics nears FDA decision with stronger ivonescimab survival signal
Ivonescimab’s updated HARMONi survival trend strengthens before the FDA’s November decision, but key statistical details remain undisclosed.
Pharma & Biotech
Signatera detected 90% of recurrences versus 55% for AMERK. Is Merkel cell surveillance about to change?
Signatera showed 90% sensitivity versus 55% for AMERK in Merkel cell carcinoma, strengthening Natera’s case for broader MRD surveillance.
Pharma & Biotech
D&D Pharmatech’s MASH candidate gains credibility as Phase 2 findings enter peer review
Peer-reviewed Phase 2 data link zabopegdutide to rapid liver fat and stiffness reductions, while Phase 3 validation remains the decisive test.
Pharma & Biotech
Arcus Biosciences’ August 5 call looks routine, but its biggest pipeline test is approaching
Arcus Biosciences will report Q2 results on August 5 as investors assess casdatifan progress, pipeline execution and its cash runway.
Pharma & Biotech
Why Vasomune is taking its AV-001 vascular leak strategy into combat casualty medicine
Vasomune Therapeutics will present Pegevongitide at a major military health symposium, positioning vascular leak as a shared target across burns, shock, trauma and acute respiratory distress syndrome.